Table 2. The treatment of psoriasis vulgaris (induction therapy).
Severity of psoriasis | Treatment | Effectiveness*1 | Evidence level*1 | |
Agent | Administration | |||
Mild*2 | Dithranol | Local | ++ | 2 |
Corticoids (class II-IV agents) | Local | ++++ | 1 | |
Vitamin D3 and its analogues | Local | +++ | 1 | |
Moderate to severe | UVB | Local | +++ | 2 |
PUVA | Local | +++ to ++++ | 2 | |
Acitretin | Oral | + | 3 | |
Ciclosporine | Oral | ++ to +++ | 1 | |
Fumarates | Oral | ++ | 2 | |
Methotrexate | Preferably subcutaneous | ++ | 3 | |
Efalizumab | Subcutaneous | + | 1 | |
Etanercept | Subcutaneous | + to ++ | 1 | |
Infliximab | Intravenous | +++ to ++++ | 1 | |
Adalimumab | Subcutaneous | +++ to ++++ | (1)*3 |
*1 Assessment according to S3 guidelines (14); evaluation scale: – (poor), +/–, +, ++, +++, ++++ (good).
*2 Topical therapy is also used for moderate to severe psoriasis in combination with UV or systemic therapy.
*3 Assessment on the basis of published studies; because this agent had not been approved when the S3 guidelines were written, it is not evaluated there.